SCHD - ETF AI Analysis
Top Page
Schwab US Dividend Equity ETF (SCHD)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The fund has delivered strong gains so far this year and in recent months, showing solid momentum.
Low Expense Ratio
The ETF charges a very low fee, which helps investors keep more of their returns over time.
Defensive Sector Mix
Heavy exposure to health care and consumer defensive companies can help provide stability during market downturns.
Negative Factors
Single-Country Focus
Almost all assets are invested in U.S. companies, offering little geographic diversification.
Concentration in Top Holdings
A relatively small group of large positions makes up a significant share of the portfolio, increasing reliance on those companies.
Mixed Performance Among Key Stocks
Some major holdings have shown weak or negative performance this year, which can drag on overall returns if the trend continues.
SCHD vs. SPDR S&P 500 ETF (SPY)
AUM114.14B
RegionNorth America
Expense Ratio0.06%
Beta0.48
IssuerSchwab
Inception DateOct 20, 2011
Dividend Yield3.07%
Asset ClassEquity
Index TrackedDow Jones U.S. Dividend 100
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume22,199,040
30 Day Avg. Volume23,020,305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
37.77Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering99
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SCHD Summary
Schwab US Dividend Equity ETF (SCHD) is a fund that follows the Dow Jones U.S. Dividend 100 Index, focusing on large U.S. companies that pay steady, reliable dividends. It holds well-known names like Coca-Cola and Procter & Gamble, along with firms in health care, consumer goods, energy, and technology. Someone might invest in SCHD to build a simple, diversified income stream, with the potential for long-term growth as these companies grow and raise their payouts. A key risk is that stock prices and dividends can still go up and down with the overall market and the health of the U.S. economy.
How much will it cost me?SCHD has an expense ratio of 0.06%, which means you’ll pay $0.60 per year for every $1,000 invested. This is lower than average because SCHD is passively managed, tracking an index rather than relying on active stock picking.
What would affect this ETF?SCHD's focus on U.S. companies with strong dividend performance could benefit from stable economic growth and favorable corporate earnings, particularly in sectors like Consumer Defensive and Health Care, which are less sensitive to economic downturns. However, rising interest rates or regulatory changes affecting dividend payouts could negatively impact its performance, especially in sectors like Energy and Financials. Additionally, shifts in consumer spending or geopolitical tensions could influence the top holdings, such as PepsiCo, Chevron, and Lockheed Martin.
SCHD Top 10 Holdings
SCHD is leaning heavily on steady U.S. dividend stalwarts, with health care, consumer defensive, and energy names setting the tone. Merck and Amgen have been rising, giving the fund a solid lift from the pharma corner, while Chevron and ConocoPhillips add fuel with strong, recently improving energy performance. On the defensive side, Coca-Cola and Procter & Gamble are more steady than exciting, helping smooth volatility but not driving big gains. UnitedHealth and Verizon have been mixed to lagging, occasionally acting as a brake on the fund’s otherwise resilient, U.S-focused dividend engine.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Texas Instruments | 4.54% | $5.12B | $254.91B | 56.57% | 78 Outperform | |
| Procter & Gamble | 4.37% | $4.93B | $364.85B | 5.25% | 69 Neutral | |
| Chevron | 4.32% | $4.87B | $433.33B | 46.98% | 71 Outperform | |
| Coca-Cola | 4.29% | $4.83B | $395.83B | 37.20% | 75 Outperform | |
| Conocophillips | 4.27% | $4.81B | $170.27B | 69.41% | 78 Outperform | |
| Qualcomm | 4.19% | $4.72B | $190.50B | 5.30% | 80 Outperform | |
| UnitedHealth | 4.08% | $4.60B | $365.02B | 12.57% | 72 Outperform | |
| Merck & Company | 4.01% | $4.51B | $358.21B | 72.13% | 80 Outperform | |
| Amgen | 3.97% | $4.47B | $234.65B | 44.74% | 77 Outperform | |
| Abbott Laboratories | 3.84% | $4.33B | $181.14B | -18.40% | 73 Outperform |
SCHD Technical Analysis
Positive
―
Price Trends
33.82
Positive
33.04
Positive
31.56
Positive
Market Momentum
0.04
Negative
67.20
Neutral
94.30
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SCHD, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.17, equal to the 50-day MA of 33.82, and equal to the 200-day MA of 31.56, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 67.20 is Neutral, neither overbought nor oversold. The STOCH value of 94.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCHD.
SCHD Peer Comparison
Comparison Results
Performance Comparison
SCHD
Schwab US Dividend Equity ETF
34.35
8.27
31.71%
VYM
Vanguard High Dividend Yield Index ETF
―
―
―
DVY
iShares Select Dividend ETF
―
―
―
SDY
SPDR S&P Dividend ETF
―
―
―
HDV
iShares Core High Dividend ETF
―
―
―
FDVV
Fidelity High Dividend ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents